Abstract: The present invention relates to a method for treating a patient suffering from a mental disorder, comprising administering to the patient an effective 5-HT1A agonistic and 5-HT2 antagonistic amount of a compound having the formula (I): or a pharmacologically active salt thereof.

Abstract: Novel compounds of the formula: ##STR1## wherein R is selected from saturated or unsaturated alkyls, saturated or unsaturated cycloalkyls, heterocyclic compounds, or from (a) or (b) wherein G is carbon wherein G is carbon or nitrogen; m is 0-10, wherein R.sub.1, R.sub.2, and R.sub.3 are the same or different and selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbons or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl and the pharmacologically acceptable salts thereof; being useful for treating disorder in the central nervous system.

Abstract: The present invention concerns compounds of the formula (I) ##STR1## wherein Ar are the same or different and are a phenyl group, optionally substituted with fluorine, or a pyrid-4-yl group, R.sub.1 and R.sub.2 are the same or different and are selected from hydrogen or lower alkyl, n is 2 or 3, X is nitrogen or methine and A is pyrimid-2-yl or a substituted or unsubstituted pyridyl group. The compounds are useful for treating mental disorders.

Abstract: Compounds of general formula (I) are useful for treating mental disorders, wherein R.sub.1 and R.sub.2 are the same or different and selected from hydrogen or lower alkyl; Ar are the same or different and selected from pyridyl and phenyl groups, n is 1 or 2, X is nitrogen or methine. When X is nitrogen, Y is methylene. When X is methine, Y is selected from nitrogen or oxygen. A is selected from carboxylic derivatives. The pharmacologically active salts of formula (I) are also embraced.

Abstract: The present invention concerns novel compounds of the general formula; ##STR1## wherein R.sub.1 is halogen or hydrogen and R.sub.2 is halogen; X is either oxygen, sulfor or methyleneR.sub.3 and R.sub.4 are the same or different and selected from hydrogen and lower alkyl;n is 2 or 3;A is selected from the following pyrimidyl or pyridyl groups ##STR2## wherein R.sub.5 is selected from hydrogen, lower alkyl or halogen; R.sub.6 and R.sub.7 are the same or different and selected from hydrogen, halogen, lower alkyl, electron donor groups such as lower alkoxy or hydroxy, electron acceptor groups such as cyano, nitro, trifluoromethyl, COOR.sub.8, CONR.sub.9 R.sub.10 or CO-B;wherein R.sub.8 is hydrogen or lower alkyl;R.sub.9 and R.sub.10 are the same or different and selected from hydrogen, lower alkyl and cycloalkyl;B is selected from ##STR3## wherein m is 1, 2, 3 or 4. R.sub.11 is selected from hydrogen or lower alkyl, and the pharmacologically active salts thereof.